AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31538453
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment in 2° and 3° quadrants)
Trial: 27902641
Drug: Neostigmine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (50 μg/kg)
Trial: 27902641
Drug: Neostigmine followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine followed by Sugammadex (50 μg/kg neostigmine, then 2 mg/kg sugammadex after 3 min)
Trial: 19615696
Drug: Interferon beta
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta (IFNbeta) treatment
Trial: 17302058
Drug: Wendan Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wendan Tablet (WT)
Trial: 12765886
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg kg(‐1))
Trial: 11104345
Drug: Supratentorial radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supratentorial radiation dose of 25 Gy
Trial: 11104345
Drug: Supratentorial radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supratentorial radiation dose of 35 Gy
Trial: 1651860
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg on day 1, plus 250 mg/day on days 2-5)
Trial: 1651860
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid (625 mg every eight hours for ten days)
Trial: 7042074
Drug: Peptichemio (75-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptichemio (75-100 mg/m2 IV q 3-4 weeks)
Trial: 7042074
Drug: L-PAM (30-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PAM (30-40 mg/m2 IV q 3-4 weeks)
Trial: 3898925
Drug: Intravenous salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous salbutamol
Trial: 31658494
Drug: Intravenous tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous tobramycin
Trial: 28882926
Drug: ProAsk intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ProAsk intervention delivered on a tablet device
Trial: 24975366
Drug: Risperidone (single-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (single-dose, two-period crossover study)
Trial: 27092789
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg once a day for 12 weeks
Trial: 21501328
Drug: Tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine ER 4 mg once a day for 12 weeks
Trial: 19709754
Drug: Escitalopram, 10
RxNorm normalized name: Escitalopram, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram, 10 mg
Trial: 19709754
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of escitalopram and bupropion
Trial: 15117326
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b plus ribavirin (RBV) 1000-1200 mg/day for 48 weeks (Study 1)
Trial: 15117326
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b plus ribavirin (RBV) 1000-1200 mg/day for 4 weeks followed by three times weekly dosing for 44 weeks (Study 2)
Trial: 15117326
Drug: RBV dose
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RBV dose reduction
Trial: 15117326
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b daily use
Trial: 11208843
Drug: 4-week chemotherapy
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week chemotherapy regimen (vincristine and actinomycin D)
Trial: 11208843
Drug: 8-week chemotherapy
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8-week chemotherapy regimen (vincristine and actinomycin D)
Trial: 11208843
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (NFT) for stage I favorable histology (n = 5)
Trial: 7883388
Drug: Meropenem 500
RxNorm normalized name: meropenem 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 500 mg t.i.d. intravenously for 3-21 days (mean 5.4 days)
Trial: 7883388
Drug: Imipenem/cilastatin 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin 500 mg/500 mg t.i.d. intravenously for 3-17 days (mean 5.1 days)
Trial: 3284283
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine chewing gum (n = 62)
Trial: 3284283
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg nicotine chewing gum (n = 54)
Trial: 3284283
Drug: Group counselling
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group counselling with nicotine gum (2 mg or 4 mg)
Trial: 21115872
Drug: Topotecan Weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan Weekly (Tw) 4 mg/m²/week administered on days 1, 8, and 15
Trial: 21115872
Drug: Conventional 5-Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 5-Day Schedule (Tc) 1.25 mg/m²/day on days 1 to 5
Trial: 21115872
Drug: Topotecan Weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan Weekly (Tw)
Trial: 15936996
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of atorvastatin daily
Trial: 16854404
Drug: Recutin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recutin (100 mg)
Trial: 16854404
Drug: Polybutin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polybutin (100 mg)
Trial: 8665993
Drug: BAY t
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY t 7207 (20 mg)
Trial: 2225152
Drug: Indomethacin 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 0.5% eye drops administered three times a day from the day prior to operation to the 10th day after operation
Trial: 2225152
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered three times a day from the day prior to operation to the 10th day after operation
Trial: 25546164
Drug: Voglibose/metformin fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose/metformin fixed-dose combination (FDC)
Trial: 25546164
Drug: Coadministered individual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coadministered individual voglibose and metformin tablets
Trial: 23690755
Drug: Facilitation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitation of local stakeholder groups (laywomen facilitated monthly meetings for 3 years)
Trial: 17338610
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 30 mg/kg intravenously as a bolus followed by a continuous infusion of 10 mg/kg/hr starting 15 minutes before induction of sedation.
Trial: 11370752
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of weekly fluoride rinsing (test group)
Trial: 11370752
Drug: Weekly rinsing
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly rinsing with 0.2% sodium fluoride solution (control group)
Trial: 9112137
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg x kg‐1 ketorolac
Trial: 9112137
Drug: 0.9 mg
RxNorm normalized name: estradiol 0.9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg x kg‐1 ketorolac
Trial: 1439622
Drug: Arthrotec (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrotec (50 mg diclofenac + 200 micrograms misoprostol)
Trial: 4091997
Drug: Ethanol consumption
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol consumption (80 g per day)
Trial: 23344135
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (statutory drug education) for LR youth
Trial: 21155908
Drug: Cross-intolerance (CI)
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-intolerance (CI) to NSAIDs, primarily involving propionic acid derivatives like ibuprofen.
Trial: 16042878
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg entecavir
Trial: 18554238
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg entecavir
Trial: 11550573
Drug: Standard inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard inactivated whole‐virion influenza vaccine (0.5 ml subcutaneously in a single injection)
Trial: 11550573
Drug: Standard inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard inactivated whole‐virion influenza vaccine (intranasally in two administrations)
Trial: 11550573
Drug: Standard inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard inactivated whole‐virion influenza vaccine (intranasally)
Trial: 11550573
Drug: Preparation 'Amber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation 'Amber elixir plus'
Trial: 8112372
Drug: Intravenous 14C‐fosinoprilat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 14C‐fosinoprilat (7.5 mg)
Trial: 8112372
Drug: Oral 14C‐fosinopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 14C‐fosinopril sodium (10 mg)
Trial: 8112372
Drug: Oral fosinopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fosinopril sodium (10 mg)
Trial: 3086388
Drug: Rifampin therapy
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin therapy (5 days) in combination with penicillin or erythromycin (10-14 days)
Trial: 31926037
Drug: Blood donors
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood donors with lead concentrations over the limit for transfusions in premature infants (0.09 μmol/L)
Trial: 31926037
Drug: Blood donors
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood donors with mercury concentrations over the suggested limit (23.7 nmol/L)
Trial: 31926037
Drug: Blood donors
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood donors with cadmium concentrations over the limit (16 nmol/L)
Trial: 31926037
Drug: Blood donors
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood donors with perfluorooctanoate (PFOA) concentrations over the suggested limit (0.91 ng/mL)
Trial: 31926037
Drug: Blood donors
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood donors with perfluorooctane sulfonate (PFOS) concentrations over the suggested limit (0.91 ng/mL)
Trial: 23609425
Drug: Sputum induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sputum induction by inhalation of hypertonic saline
Trial: 19451828
Drug: Standard-of-care antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care antipsychotics
Trial: 16433729
Drug: Transdermal alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal alcohol monitoring device (anklet)
Trial: 16433729
Drug: Self-reported drinking
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported drinking log and transdermal alcohol monitoring device
Trial: 16433729
Drug: Transdermal alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal alcohol monitoring device
Trial: 14654535
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (40 mg/instillation)
Trial: 10838647
Drug: Meningococcal C
RxNorm normalized name: meningococcal conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal C conjugate vaccine (0.5 mL doses, groups 1 and 2; n=60 each)
Trial: 10838647
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B control vaccine (group 3; n=62)
Trial: 10452046
Drug: Local delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local delivery of drugs (prednisolone and procaine) during tissue expansion
Trial: 10452046
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no local drug delivery)
Trial: 1589555
Drug: Trihexyphenidyl (THP)
DrugBank: Trihexyphenidyl (DB00376)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trihexyphenidyl (THP) 2 mg, 4 mg
Trial: 1589555
Drug: Biperiden (BPD)
DrugBank: Biperiden (DB00810)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biperiden (BPD) 1 mg, 2 mg, 5 mg
Trial: 1589555
Drug: Mazaticol (MZC)
RxNorm normalized name: mazaticol
DrugBank: Mazaticol (DB13448)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mazaticol (MZC) 4 mg, 8 mg
Trial: 1589555
Drug: L-dopa (LDP)
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: L-dopa (LDP) 100 mg
Trial: 1589555
Drug: Bromocriptine (BMC)
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromocriptine (BMC) 1.25 mg, 2.5 mg
Trial: 1589555
Drug: Amantadine (AMD)
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine (AMD) 100 mg
Trial: 1589555
Drug: Amitriptyline (ATP)
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline (ATP) 25 mg
Trial: 1589555
Drug: Haloperidol (HPD)
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol (HPD) 3 mg
Trial: 1589555
Drug: Diazepam (DZP)
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam (DZP) 3 mg
Trial: 3896595
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg, b.d.)
Trial: 29746229
Drug: Intraperitoneal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal and intravenous paclitaxel plus S-1 (IP); intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 plus S-1 80 mg/m2 per day on days 1 to 14 for a 3-week cycle
Trial: 29746229
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus cisplatin (SP); S-1 80 mg/m2 per day on days 1 to 21 plus cisplatin 60 mg/m2 on day 8 for a 5-week cycle
Trial: 24665241
Drug: I.V ramosetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V ramosetron 0.3 mg
Trial: 24665241
Drug: I.V Ondansetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V Ondansetron 4 mg
Trial: 23460233
Drug: Deferiprone monotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone monotherapy, average dose 79.1±4.3 mg/kg/day
Trial: 23460233
Drug: Deferiprone monotherapy
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone monotherapy
Trial: 7653685
Drug: Counseling plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling plus supplemental drug counseling
Trial: 791192
Drug: BA‐34647 (experimental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BA‐34647 (experimental antispasticity drug)
Trial: 31847158
Drug: Soft tissue
RxNorm normalized name: INSULIN DETEMIR 14.2 mg in 1 mL SOFT TISSUE IMPLANT [Levemir]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft tissue therapy (additional therapy program alongside standard physical therapy)
Trial: 27368000
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine (5 mg/kg)
Trial: 15587094
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.7 mg/kg)
Trial: 25144127
Drug: Intracameral MFLX
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral MFLX (150 μg/mL) in left eye, balanced salt solution in right eye (Group A)
Trial: 25144127
Drug: Intracameral MFLX
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral MFLX (500 μg/mL in right eye, 150 μg/mL in left eye) (Group B)
Trial: 25144127
Drug: Intracameral MFLX
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral MFLX (150-500 μg/mL)
Trial: 22124104
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus surgery (gemcitabine 1,250 mg/m² days 1 and 8 every 3 weeks plus cisplatin 75 mg/m² day 1 every 3 weeks followed by surgery)
Trial: 17488461
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia (TA)
Trial: 31841026
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of dobutamine and terlipressin
Trial: 31152372
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL boluses of bupivacaine 0.125% with fentanyl 2 µg·mL-1
Trial: 24125150
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol 80 μg
Trial: 24125150
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol 160 μg
Trial: 19683881
Drug: Artelon implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artelon implant
Trial: 19683881
Drug: APL tendon
RxNorm normalized name: Bos taurus tendon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APL tendon suspension interposition arthroplasty
Trial: 18184530
Drug: Basal Supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal Supported Oral Treatment (BOT) - insulin glargine combined with glimepiride and metformin
Trial: 18184530
Drug: Conventional Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Therapy (CT) - premixed insulin
Trial: 1785707
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (5 micrograms.kg‐1 during the first hour, and 0.3 microgram.kg‐1.h‐1 thereafter)
Trial: 7265042
Drug: Standard film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard film taken during arterial time after contrast medium injection
Trial: 28422864
Drug: Ketamine (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (100, 200, 1000 ng/mL)
Trial: 28422864
Drug: Morphine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (200 ng/mL)
Trial: 16759047
Drug: Treatment interruption
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment interruption
Trial: 24797262
Drug: Treatment interruption
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment interruption in patients with low on-treatment levels of serum IFN‐γ
Trial: 12190751
Drug: Oral flumazenil
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral flumazenil
Trial: 8813983
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with additional biofeedback training (CT+BF)
Trial: 2861567
Drug: OKT3 monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKT3 monoclonal antibody treatment for acute rejection, daily for a mean of 14 days, with concomitant lowering of other immunosuppressive drugs.
Trial: 2861567
Drug: Conventional high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional high-dose steroids treatment for acute rejection.
Trial: 2861567
Drug: OKT3 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OKT3 treatment group.
Trial: 2861567
Drug: Conventional high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional high-dose steroids treatment group.
Trial: 22842057
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of tranexamic acid (5 g in 100 ml saline solution)
Trial: 22842057
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 ml saline solution)